Comparison of MRI/US Fusion Targeted Biopsy and Systematic Biopsy in Biopsy-Naïve Prostate Patients with Elevated Prostate-Specific Antigen: A Diagnostic Study.

Content Provider	Europe PMC
Author	Huang, Chen Huang, Yuhua Pu, Jinxian Xi, Qilin Wei, Xuedong Qiu, Feng Wang, Ximing Zhao, Xiaojun Guo, Linchuan Hou, Jianquan
Copyright Year	2022
Abstract	PurposeThis study aimed to compare the detection rate of prostate cancer (PCa) between targeted biopsy and systematic biopsy.Patients and MethodsA total of 671 patients who underwent both targeted biopsy and systematic biopsy were included in this study. The stratified analysis was conducted based on Prostate Imaging Reporting and Data System (PIRADS) scores, region of interest load (ROI-load).ResultsThere was no statistical difference in the detection rate of PCa patients between systematic biopsy and targeted biopsy (44.41% vs 45.6%, P>0.05), while the detection rate of targeted biopsy in clinically significant PCa (csPCa) patients was slightly higher than that of systematic biopsy (40.83% vs 38.15%, P=0.033). Stratified analysis indicated that targeted biopsy was more advantageous in csPCa patients with PIRADS score ≥ 4 and ROI-load > 5%. The comparison of diagnostic sensitivity of systematic biopsy and targeted biopsy demonstrated that targeted biopsy was more sensitive than systematic biopsy to diagnose PCa (Z=2.110, P=0.035) at ROI-load ≤ 5%. In addition, ROI-load may be a better targeted biopsy indicator than ROI diameter for the diagnosis of PCa (Z=2.168, P=0.030).ConclusionMRI/US fusion targeted biopsy may be more suitable for PCa detection than systematic biopsy in patients with low ROI-load.
Page Count	13
Volume Number	14
PubMed Central reference number	PMC9007594
PubMed reference number	35431579
Journal	Cancer Management and Research [Cancer Manag Res]
e-ISSN	11791322
DOI	10.2147/CMAR.S350701
Language	English
Publisher	Dove
Publisher Date	2022-04-08
Access Restriction	Open
Rights License	This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). © 2022 Huang et al.
Subject Keyword	multiparametric-MRI targeted biopsy prostate cancer detection
Content Type	Text
Resource Type	Article
Subject	Oncology